News By Tag
News By Location
Autotelic Lab to present at ENDO 2012
Autotelic Lab will be presenting data on point of care diagnostic devices for FSH and BNP as potential diagnostic biomarker screening for ovarian cancer
Here, Dr. Larn Hwang and colleagues describe the development of rapid point-of-care tests for detection of these hormones that are quantitative and applicable to plasma, serum, as well as urine. As rapid point-of-care tests, these tests would allow for more effective screening for ovarian cancer. These findings will be presented at The Endocrine Society’s 94th Annual Meeting & Expo (ENDO), June 23-26, 2012, Houston, TX.
Abstract # 851968: The Hormones BNP and FSH in Ovarian Cancer. Larn Hwang, Kouros Motamed, Chao Hsiao, and Vuong Trieu. This poster has been scheduled for presentation on Monday, June 25, 2012. POSTER SESSION: Biomarkers, Metastasis & Tumor Progression, & Tumorigenesis - II (1:30 PM-3:30 PM). Presentation Time: 1:30 pm. Room: Expo
About ENDO 2012:
The Endocrine Society's 94th Annual Meeting & EXPO takes place in Houston, TX on June 23-26, 2012. ENDO 2012 is a unique opportunity to learn about the latest research in fields as diverse as obesity, endocrine disruptors, diabetes, growth hormones, sex steroids, thyroid cancer and much more. Held at the George R. Brown Convention Center, more than 7,500 scientists and clinicians from all over the world will assemble for this global and premier meeting of hormone research, health science and endocrinology.
About Autotelic Lab:
Autotelic lab is a provider of quantitative point-of-care testing solutions including quantitative lateral flow cassettes, lateral flow reader, as well as a quantification service. Our product lines include emergency care, women's health, cancer biomarkers, and regenerative medicine. Our offerings are uniquely configured to accept multiple readers to satisfy all possible field conditions; from highly specialized requiring specificity and sensitivity to low tech without access to normal laboratory resources. Our mission is to put testing into the hands of primary care providers and patients. These tests are simple to use and require no specialized equipment or trained personnel. They are rapid with results within 20 minutes of blood collection. They are convenient and can be deployed at home, in doctor’s office, in emergency rooms, or in centralized laboratories. Moreover, they are quantitative with a linear response range similar to tests performed at centralized laboratories.
These proprietary diagnostic devices deployed at point-of-care are being used for therapeutic drug monitoring by our partner―Biomiga Diagnostics―
The executives of Autotelic Lab are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing. With more than a decade of drug development experience, the leadership team has expertise ranging from basic/applied research, preclinical/
Kouros Motamed, Ph.D.
Chief Executive Officer